Published • loading... • Updated
Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinks
Summary by foreignpolicyjournal.com
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
Novo Nordisk (NYSE: NVO) Scraps Two Heart-Failure Drug Trials As Cardiovascular Pipeline Shrinks
Novo Nordisk A/S (NYSE: NVO) has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab, dealing another blow to the Danish drugmaker’s diversification strategy. The decision came after an independent data monitoring committee concluded there was a “low likelihood” the two heart-failure studies would produce results different from an earlier failed trial. That […]
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
